Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Leona M. and Harry B. Helmsley Charitable Trust | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
International Diabetes Center (IDC) proposes a preference and usability study of glucose data acquisition and reporting, evaluating streamlined standardized cloud-based glucose reporting including work flow as well as patient and clinician preference at Type 1 Diabetes (T1D) Exchange sites to enhance standard Ambulatory Glucose Profile (AGP) reporting. This phase 2 project assesses the efficacy of standardized glucose data report generation and preferred report presentation format; both are necessary to increase use of continuous glucose monitoring (CGM) data to improve care processes and outcomes for Type 1 diabetes.
Patient participation in diabetes treatment has relied upon episodic self-monitoring of blood glucose (SMBG). SMBG assists patients and clinicians with adjustments of insulin, identification of hypoglycemia, nutritional intake and activity in order to optimize diabetes control. SMBG however is subject to bias dependent upon the testing frequency and timing. In contrast, continuous glucose monitoring (CGM) systems capture continuous 24-hour glucose data uninterrupted and unbiased. It provides valuable information about daily/nightly alterations in glucose patterns. Unfortunately SMBG, CGM and insulin pump devices have proprietary software with unique data standards, acquisition methods, reports, and graphic displays. These differences make evaluation and comparison of SMBG or CGM data difficult for clinicians and patients. IDC created an Ambulatory Glucose Profile (AGP) report to reduce challenges of device specific reports through a standardized report which is produced from any device with streamlined graphic displays of glucose trends.
The phase 1 project (2012), gathered expert stakeholders (clinical, research, industry, patients) who validated data standards and recommended changes to the CGM-AGP reports. These changes are now integrated into a secure cloud-based infrastructure for AGP reporting.
Phase 2 of this project is a usability and preference study of glucose reporting systems. It will include an in depth study of 6 T1D Ex clinical sites. The T1D Exchange Clinic Network was formed to support the development of a large registry of adults and children with type 1 diabetes for the purpose of conducting multiple studies proposed by T1D Exchange investigators, and other researchers, patients, and companies.
The 6 sites will be selected for an in-depth study utilizing middleware data collection services (Diasend or SweetSpot) to facilitate efficient collection of data from diverse devices. These middleware solutions integrate with the captūrAGP system to automatically produce an AGP report. These sites will test the feasibility of AGP cloud reporting while collecting patient and clinician opinions on report preference. All 6 sites participating in phase 2 will collect patient and clinician preference measures. Two study sites will undergo time in motion (TIM) measurement and workflow mapping of current process. This TIM sub-study includes workflow mapping of current and cloud-based processes utilizing Toyota Lean (Kaizen) methodology. Sites 3 - 6 will receive enhanced designs through the adaptive trial method with learnings applied from sites 1 and 2.
A key deliverable of this study is patient and clinician insight into their utilization of CGM reporting technologies. Recognizing that adoption of technology is often stymied by time constraints, report reliability and ease of interpretation, these variables will be examined. The goal of phase 2 is to analyze the viability of standard reporting and to evaluate preference (patient and clinicians) for and perceived value of different types of glucose pattern reports (AGP vs. device) including clinical practice time saved.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous Glucose Monitoring | Other | Participants will wear Continuous Glucose Monitoring for two weeks. |
|
| Self Monitoring Blood Glucose | Other | Participants will self test for two weeks. |
|
| Clinicians | Other | Clinicians completing study visits. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Continuous Glucose Monitor | Device | CGM device for measurement of interstitial glucose on a 24/7 continuous cycle. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports | Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey. | At the end of the two week SMBG or CGM period |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard Bergenstal, MD | Park Nicollet | Principal Investigator |
| Deborah Mulllen, PhD | Park Nicollet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eda Cengiz | New Haven | Connecticut | 06511 | United States | ||
| Larry Deeb |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Continuous Glucose Monitoring | Participants will wear Continuous Glucose Monitoring for two weeks. Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle. |
| FG001 | Self Monitoring Blood Glucose |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Self Monitoring Blood Glucose | Device | Participants will use their own SMBG device. |
|
| Clinician | Other | Survey of clinicians after study visits |
|
| Tallahassee |
| Florida |
| 32308 |
| United States |
| Henry Ford | Detroit | Michigan | 48202 | United States |
| Park Nicollet International Diabetes Center | Minneapolis | Minnesota | 55416 | United States |
| The Diabetes Center, PLLC | Ocean Springs | Mississippi | 39564 | United States |
| St. Vincent's | Billings | Montana | 59101 | United States |
| Columbia University | New York | New York | 10032 | United States |
Participants will self test for two weeks. Self Monitoring Blood Glucose: Participants will use their own SMBG device. |
| FG002 | Clinicians | Clinicians completing study AGP visits. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Continuous Glucose Monitoring | Participants will wear Continuous Glucose Monitoring for two weeks. Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle. |
| BG001 | Self Monitoring Blood Glucose | Participants will self test for two weeks. Self Monitoring Blood Glucose: Participants will use their own SMBG device. |
| BG002 | Clinicians | Clinicians completing the study visits. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports | Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey. | Posted | Number | participants | At the end of the two week SMBG or CGM period |
|
|
|
1 year and 6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Continuous Glucose Monitoring | Participants will wear Continuous Glucose Monitoring for two weeks. Continuous Glucose Monitor: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle. | 0 | 70 | 0 | 70 | ||
| EG001 | Self Monitoring Blood Glucose | Participants will self test for two weeks. Self Monitoring Blood Glucose: Participants will use their own SMBG device. | 0 | 70 | 0 | 70 | ||
| EG002 | Clinicians | Clinicians completing study visits. Clinician: Survey of clinicians after study visits | 0 | 17 | 0 | 17 |
Not provided
Not provided
This is a survey of patient and clinician preference and as such is subject to traditional survey biases (social desirability, hawthorne effect, etc.).
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Deborah Mullen | Park Nicollet Institute | 952-993-2070 | deborah.mullen@parknicollet.com |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015190 | Blood Glucose Self-Monitoring |
| D009720 | Nurse Clinicians |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008991 | Monitoring, Physiologic |
| D000085263 | Self-Testing |
| D012648 | Self Care |
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
| D000072184 | Nurse Specialists |
| D009726 | Nurses |
| D006282 | Health Personnel |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|